Member Info for Flippineck

CJ62. Yes, long may it continue. It does feel like we’ve turned a corner here and there is much potential for good news to drop in the not too distant future.

GLA

It’s laughable really. A mass of buy and sell signals over the last few months. Anybody following those recs each time probably lost money. Not to mention being stressed out!

Some of this mornings posts implying a share price drift down haven’t proved very accurate either.

Me too. How can we say the “ shares are not in sticky hands”?

We have had a decent rise, some folks are bound to be tempted to take a profit but we have no idea who those sellers are.

However anybody selling now could be missing out on the chance of a lifetime. We all have a choice.

It seems a number of people believe, or want us to believe, a placing will be needed to cover funding. Often suggested at ridiculously low prices.

We have been told that we are financed into early 2026. We are told of multiple on-going discussions. Is it not far more likely that licensing deals/ partnerships will cover funding?

Poor old Motorway Rob. I think he turned off at the wrong junction some time ago!

Only a couple of months back he was suggesting 20-25 p here. Hope nobody listens to this trading “expert”!

Cheers for that information.

We were always told our trial would be data rich, so I think we have Al and Fiona to thank for that.

It seems Myles McNulty’s twitter post of 9 May was spot on. I see he has tweeted again today.

Whilst we know nothing is certain in life ( or investing!) it does seem we now have a clearer direction of travel. CC has reshaped the company and done her best to signpost the way ahead.

For investors you either believe in what we have or you don’t.

GLA

At the end of the day according to RNS 9 June

The company have given us a roadmap and they are following it. No surprises.

Traders, who know little about the company, pop up to enlighten us but a look at their posting history reveals all! Why do they waste their time here ? Ignore.

GLA

I totally agree Captain. Hurst gives a factual and informative post, yet almost immediately and predictably gets a sarcastic put down from Timster.

Timster has more that 20 thousand posts to his name. Some are excellent but the majority are insulting or sarcastic to others. That isn’t an attractive personality trait. My opinion only.

Wyn and Thorn are sharing the same seat, for sure.

A very good point Unicorno, when you think about it Avacta could create even bigger news impact if they were able to quote that much higher % tumour volume reduction. I suppose it would be difficult as tumours may be unusual shapes.

Delighted with this news but to anybody who reads RNS’s and watches company presentations this isn’t a massive surprise.

It does illustrate, however, that those low lives, who crawl out of the woodwork from time to time, have nothing whatsoever to give to this chat board.

GLA

CC was pretty clear in the presentation that they have set ambitious timelines for AVA 6103.

They have learned from AVA 6000 trial and that, together with Tempus input, should speed things along. IMO.

AVA 6000 is the “pathfinder”.

In the Q and A the other day CC stressed the importance of protecting the IP for AVA 6103. This will impact the whole of the future pipeline. As a Top1 inhibitor it is much more broadly applicable than Top1 and the sheer number of disease settings creates a huge addressable market.

She implied that the true value of the above will only be achieved by dosing in the clinic. I believe she knows it is important to progress this further and has no wish to do a quick deal on the cheap. It seems pretty clear there is already a lot of interest.

GLA

Looking like W timed his exit perfectly!!

H4, yes he did basically say Coris sale was being finalised.

CC said yesterday that all trial sites were keen to be involved in AVA6103. That indicates to me they are happy with AVA6000 and see the massive potential here as the platform develops.

Our science is key and with Tempus things will move much faster. The science will unlock the funding.IMO.

Cohorts!!

Phase 1b expansion shorts refers to three indications, including soft tissue sarcomas. Only refers to release of initial data with regard to SGC and TNBC.

As has been said before what is happening with high grade soft tissue sarcoma ?